134 related articles for article (PubMed ID: 26897354)
1. Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy.
Foryś U; Bodnar M; Kogan Y
J Math Biol; 2016 Oct; 73(4):867-83. PubMed ID: 26897354
[TBL] [Abstract][Full Text] [Related]
2. Combination of singularly perturbed vector field method and method of directly defining the inverse mapping applied to complex ODE system prostate cancer model.
Nave O; Elbaz M
J Biol Dyn; 2018 Dec; 12(1):983-1008. PubMed ID: 30384811
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of the Selkov oscillator.
Brechmann P; Rendall AD
Math Biosci; 2018 Dec; 306():152-159. PubMed ID: 30267735
[TBL] [Abstract][Full Text] [Related]
4. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
5. A cell kinetics model for prostate cancer and its application to clinical data and individual patients.
Dimonte G
J Theor Biol; 2010 May; 264(2):420-42. PubMed ID: 20176031
[TBL] [Abstract][Full Text] [Related]
6. Ability of intermittent androgen suppression to selectively create a non-trivial periodic orbit for a type of prostate cancer patients.
Hirata Y; Aihara K
J Theor Biol; 2015 Nov; 384():147-52. PubMed ID: 26319993
[TBL] [Abstract][Full Text] [Related]
7. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.
Chiriva-Internati M; Yu Y; Mirandola L; D'Cunha N; Hardwicke F; Cannon MJ; Cobos E; Kast WM
Prostate; 2012 Jan; 72(1):12-23. PubMed ID: 21520158
[TBL] [Abstract][Full Text] [Related]
8. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z
Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938
[TBL] [Abstract][Full Text] [Related]
9. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
10. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
11. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy.
Li X; Xu JX
J Theor Biol; 2016 Oct; 406():42-51. PubMed ID: 27338302
[TBL] [Abstract][Full Text] [Related]
12. Fractional Modeling of Cancer with Mixed Therapies.
Javeed S; Abdeen ZU; Baleanu D
Front Biosci (Landmark Ed); 2023 Aug; 28(8):174. PubMed ID: 37664940
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy of prostate cancer].
Schulze H; Sommerfeld HJ
Urologe A; 1993 Sep; 32(5):382-9. PubMed ID: 8212423
[TBL] [Abstract][Full Text] [Related]
14. A dynamical model of tumour immunotherapy.
Frascoli F; Kim PS; Hughes BD; Landman KA
Math Biosci; 2014 Jul; 253():50-62. PubMed ID: 24759513
[TBL] [Abstract][Full Text] [Related]
15. The immunotherapy of prostate and bladder cancer.
Totterman TH; Loskog A; Essand M
BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
[TBL] [Abstract][Full Text] [Related]
16. The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?
Krishchenko AP; Starkov KE
Math Biosci Eng; 2018 Oct; 15(5):1243-1254. PubMed ID: 30380309
[TBL] [Abstract][Full Text] [Related]
17. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.
Hemstreet GP; Rossi GR; Pisarev VM; Enke CA; Helfner L; Hauke RJ; Tennant L; Ramsey WJ; Vahanian NN; Link CJ
J Immunother; 2013 Jan; 36(1):57-65. PubMed ID: 23211622
[TBL] [Abstract][Full Text] [Related]
19. An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol.
Qomlaqi M; Bahrami F; Ajami M; Hajati J
Math Biosci; 2017 Oct; 292():1-9. PubMed ID: 28713023
[TBL] [Abstract][Full Text] [Related]
20. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
